Impact Therapeutics of Nanjing Closes $10 Million Funding

Impact Therapeutics, a Nanjing innovative drug developer, completed a $10 million Series B funding from China venture capitalists. The company, which specializes in novel and best-in-class cancer drugs, has several anti-tumor drugs in pre-clinical and clinical stages. Impact filed a China class 1.1 IND application for one of its candidates in late 2015. The company said it would use the new capital for clinical trials and pre-clinical projects. More details.... Share this with colleagues: // //